Entities / Company
BioNTech.
Biotechnology company from Germany
- Reports this week
- 0
- Active events
- 0
- Connections
- 57
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.Well supported4 reports1 development inside
-
Pfizer and BioNTech collaborate on COVID-19 vaccine development, alongside BNT327 joint development and AI stock benefits from tariffs.Some support1 report1 development inside
-
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.Some support3 reports5 developments inside
Gone quiet
No new reports in 90+ days-
BioNTech received authorization and recommendations for its variant-adapted COVID-19 vaccine from Health Canada and the European Medicines Agency.Some support1 report
-
BioNTech and Bristol Myers Squibb announced a partnership to advance oncology treatment and received EMA authorization for a vaccine.Some support1 report
-
NHS England has begun collaborating with BioNTech on ongoing vaccine trials.Some support1 report
-
Several companies announced major developments on July 16, including licensing deals for Merck and LaNova, a collaboration for BNT327, and the impact of Medicare Part D on Eliquis sales.Some support2 reports
-
InstaDeep was acquired by BioNTech in 2023, and Ryan Richardson has been involved in the companies since 2020, serving as CSO and being on the Board of Directors.Some support1 report
-
BioNTech is preparing for FDA approval, supported by partnerships and investments from companies like Sigma-Aldrich and Lonza, including facility builds in St. Louis and Madison.Some support1 report
-
A collaboration between Bristol-Myers Squibb and BioNTech resulted in an upfront cash payment on August 5, 2025.Some support4 reports
-
BioNTech's quarterly results led market analysts to update their financial estimates.Some support2 reports
-
The biotechs industry announced an industry growth forecast of 19% per annum.Some support1 report
-
A partnership between Bristol-Myers Squibb and BioNTech signals sustained investor confidence amid rising cancer incidence.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around BioNTech this week
News at the entities that move BioNTech mostConnections
The 3 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
CureVac Structural
BioNTech acquired CureVac, making it a wholly owned subsidiary to strengthen its mRNA cancer immunotherapy portfolio.
-
Bristol-Myers Squibb Structural
Bristol-Myers Squibb and BioNTech maintain a strategic partnership for the co-development and co-commercialization of the bispecific antibody BNT327.
-
Pfizer Operational
Pfizer and BioNTech engaged in a formal partnership and collaboration on COVID-19 vaccine development.
History
Events by the month they beganJune 2026
13 events- BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.
- Pfizer and BioNTech collaborate on COVID-19 vaccine development, alongside BNT327 joint development and AI stock benefits from tariffs.
- Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.
- BioNTech received authorization and recommendations for its variant-adapted COVID-19 vaccine from Health Canada and the European Medicines Agency.
- BioNTech and Bristol Myers Squibb announced a partnership to advance oncology treatment and received EMA authorization for a vaccine.
- NHS England has begun collaborating with BioNTech on ongoing vaccine trials.
- Several companies announced major developments on July 16, including licensing deals for Merck and LaNova, a collaboration for BNT327, and the impact of Medicare Part D on Eliquis sales.
- InstaDeep was acquired by BioNTech in 2023, and Ryan Richardson has been involved in the companies since 2020, serving as CSO and being on the Board of Directors.
- BioNTech is preparing for FDA approval, supported by partnerships and investments from companies like Sigma-Aldrich and Lonza, including facility builds in St. Louis and Madison.
- A collaboration between Bristol-Myers Squibb and BioNTech resulted in an upfront cash payment on August 5, 2025.
- BioNTech's quarterly results led market analysts to update their financial estimates.
- The biotechs industry announced an industry growth forecast of 19% per annum.
- A partnership between Bristol-Myers Squibb and BioNTech signals sustained investor confidence amid rising cancer incidence.